Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.
about
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementPomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis.Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasoneBortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence.Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaMultiple myeloma: 2016 update on diagnosis, risk-stratification, and management.The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.Latest advances and current challenges in the treatment of multiple myeloma.Extramedullary disease in plasma cell myeloma: the iceberg phenomenon.Extramedullary multiple myeloma.Pomalidomide: first global approval.Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist.Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.Pomalidomide: a review of its use in patients with recurrent multiple myeloma.Controversies in multiple myeloma: to transplant or not?Pomalidomide for multiple myeloma.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development.Pomalidomide in the management of relapsed multiple myeloma.The Critical Role of Imaging in the Management of Multiple Myeloma.The possible role of burden of therapy on the risk of myeloma extramedullary spread.Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients.Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance.Cytogenetics in multiple myeloma patients progressing into extramedullary disease.Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma.Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression.Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.Successful Intrathecal Chemotherapy Combined with Radiotherapy Followed by Pomalidomide and Low-Dose Dexamethasone Maintenance Therapy for a Primary Plasma Cell Leukemia Patient.Pomalidomide and myeloma meningitis.Cytogenetics of extramedullary manifestations in multiple myeloma.Effective treatment of pomalidomide in central nervous system myelomatosis.Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.
P2860
Q26998884-BA410BFE-EDA7-4D44-856A-26C67F764DC6Q30802505-65ECA7E3-C0C1-45F2-A657-755BE7A9C6D8Q34253548-8B7FCDA2-903B-4568-AF65-97F3CE42305CQ34263870-2A82F051-EA4D-4C1D-A29D-6FCB6036587FQ34448995-03F55433-06E8-45AF-9C56-9AB727C817D0Q35781800-D321D26E-1C5C-417F-9345-97A0960D9B3CQ36777233-02FBF689-00A9-4B66-A62C-909037FE4CCFQ36920186-9FC0AF41-1908-4687-9641-54492839308BQ37146294-455856AD-880E-40E4-B495-BA12645AE684Q37171994-F543B92F-3453-4CD3-8F47-D738AC386076Q37623809-31B14BDA-4709-4551-BB6B-1298DF0BE4B8Q37633986-560CC74E-2F3E-49A0-9CA2-DBAA440FA401Q37986287-1955E9E0-565B-45F8-986A-8182095CD2FBQ37992834-CC32DE92-7E5D-438B-9101-B4765B121B13Q38064911-9E4265C1-09F5-49D6-AC34-87EC65335CD0Q38097747-AC684C65-97E8-475C-A865-D3400624ECF1Q38111390-1DC30871-9727-4CA3-95F7-A0D4B94E57C8Q38130301-B8C26A31-E5D3-4501-9639-3872B4FACC9BQ38135264-F0B165F9-9265-4921-96E9-A6C55C0194FAQ38192969-E79D7B04-FFE7-4D03-9346-09E8622A5700Q38242006-A954D0D9-4F45-4430-A1B0-CD2FC7DC671FQ38255265-EBD4CD87-9205-4C72-9742-4C016B6201A2Q38261677-6A8AFE47-BF8A-482C-85A3-B29264FCEAC1Q38542091-6E3F1EFA-5B52-440E-97B8-3B3A417809AFQ38855510-067B64DD-A576-48D3-BF5A-2D0BAABA485FQ39186780-9D2C8A5B-4817-411B-9649-2D995E885C96Q39264310-0B556A60-0403-4E65-868B-6AC87F8D79BDQ40149390-5A2B1B42-2F5F-4876-AA3D-C7C6B0ECD4E1Q40381229-A8DB0A04-9BCD-4105-B8D2-9975A58D60F4Q40471885-57698F59-D33B-413D-945E-7B347FC35C08Q40795146-7BD043A1-8DC5-407B-A152-BB2D132162F0Q41230411-FC851885-674B-4FE6-A538-64814DF90BEBQ41288885-F9CEFBFB-B860-4CA3-B24B-67D7E3FABAD5Q41522009-A560A0F1-8847-4259-A810-DF3A8F70017BQ41702673-3B9076C2-7D17-4F28-A984-438BCB146DDDQ42223210-0E9886FD-6E27-4AED-AFB1-1DD3D61C3BB2Q42716267-717C7B83-E70A-4149-B0AB-205AEEE6DDDFQ43490917-0B282761-8A3B-42A2-BCE8-37966E5BF96BQ43619471-F8DBA13D-0A62-4792-A412-9BC7CB4FF984Q44241157-6CC62AA6-B949-49A1-86BD-348E00D6ABC6
P2860
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Incidence of extramedullary di ...... ide on extramedullary myeloma.
@en
type
label
Incidence of extramedullary di ...... ide on extramedullary myeloma.
@en
prefLabel
Incidence of extramedullary di ...... ide on extramedullary myeloma.
@en
P2093
P2860
P50
P356
P1433
P1476
Incidence of extramedullary di ...... ide on extramedullary myeloma.
@en
P2093
K Detweiler Short
P2860
P2888
P304
P356
10.1038/LEU.2011.29
P577
2011-02-25T00:00:00Z
P5875
P6179
1037466003